MedTrace Logo

CardioBBEAT - Randomized Controled Trial to Evaluate the Health Economic Impact of Remote Patient Monitoring

NCT02293252 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 621

Last updated 2016-10-25

No results posted yet for this study

Summary

The primary endpoint is the incremental cost effectiveness ratio (ICER), defined as the combined clinical endpoint "days alive and not in hospital nor stationary care per days in study" and the change in total cost compared to that of the control group.

Conditions

Interventions

DEVICE

Remote patient monitoring (Motiva)

interactive bi-directional home telemonitoring system that provides remote monitoring

Sponsors & Collaborators

  • German Federal Ministry of Education and Research

    collaborator OTHER_GOV

  • Eckhard Nagel

    lead OTHER

Principal Investigators

  • Eckhard Nagel, Prof.Dr.mult · Head of Institute for Healthcare Management and Health Science, University of Bayreuth

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2016-03-31
Completion
2016-10-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02293252 on ClinicalTrials.gov